-
Five Stocks that May End Up, umm, Higher, if Marijuana is Legalized
Wednesday, April 20, 2011 - 11:02am | 409Inhale...exhale...invest? Setting aside the personal concerns of drug warriors, the tea leaf readings suggest that marijuana will be decriminalized, if not outright legalized (and taxed for revenue) in the coming years. Savvy investors are wise to keep an eye on the future, so perhaps today's...
-
Goldman Has Notes On Forest Laboratories Earnings (FRX)
Wednesday, April 20, 2011 - 10:51am | 183Goldman Sachs is out with a research report on Forest Laboratories, Inc. (NYSE: FRX) after it reported earnings. It has a Neutral rating and a $35 price target on shares. In a note to clients, Goldman writes, "Looking past the FY4Q beat, focus rests squarely on execution of the upcoming launches...
-
Gabelli Raises Estimates On Johnson & Johnson (JNJ)
Wednesday, April 20, 2011 - 9:37am | 96Gabelli & Co. is raising its estimates on Johnson & Johnson (NYSE: JNJ) following earnings yesterday. In a note to clients, Gabelli writes, "We have raised our 2011 EPS estimate by $0.10 to $4.95 due to FX rates, a favorable Merck settlement, and core business strength. JNJ reported an...
-
News Summary
Wednesday, April 20, 2011 - 9:37am | 237Shares of Abbott Laboratories (NYSE: ABT) gained about 1% after the company reported its Q1 profit at $864 million, or $0.55 per share, down from $1 billion, or $0.64 per share, in the year-ago period. The company's net sales increased to $9.04 billion from $7.70 billion. On an adjusted basis, the...
-
Morgan Stanley Summary
Wednesday, April 20, 2011 - 9:29am | 100Morgan Stanley increased the price target on VMware (NYSE: VMW) from $98.00 to $112.00, and on Wynn Resorts (NASDAQ: WYNN) from $126.00 to $130.00. Estimates are increased on Johnson & Johnson (NYSE: JNJ). Price targets are decreased on Cree (NASDAQ: CREE) from $36.00 to $34.00, and estimates...
-
Watson Confirms Welchol Patent Challenge (WPI)
Wednesday, April 20, 2011 - 9:14am | 53Watson Pharmaceuticals (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market Colesevelam HCI 625 mg tablets. Watson's Colesevelam HCI tablets are a generic version of...
-
Watson Confirms Welchol Patent Challenge, Sankyo and Genzyme File Suit April 18 (WPI, GENZ)
Wednesday, April 20, 2011 - 9:09am | 149Watson Pharmaceuticals (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market Colesevelam HCI 625 mg tablets. Watson's Colesevelam HCI tablets are a generic version...
-
UPDATE: Oppenheimer Color On CBST Upgrade
Wednesday, April 20, 2011 - 9:03am | 145Oppenheimer, which upgraded shares of Cubist Pharmaceuticals Inc. (NASDAQ: CBST), is providing some color on the stock. “We view the recent settlement with Teva Pharmaceuticals (NASDAQ: TEVA) regarding generic Cubicin as highly favorable for CBST, providing visibility into the Cubicin franchise,”...
-
Deutsche Bank On FRX Q4 Results
Wednesday, April 20, 2011 - 8:42am | 126Deutsche Bank has issued a report following the reported F4Q11 results from Forest Laboratories (NYSE: FRX). According to the report, “Forest continues to build out a broad late-stage/commercial pipeline, and the recent acquisition of Clinical Data is another step in the right direction....
-
J.P. Morgan Reports Johnsn & Johnson turning positive
Wednesday, April 20, 2011 - 8:05am | 131According to J.P. Morgan, Johnson & Johnson (NYSE: JNJ) is turning positive. J.P. Morgan said that J&J has weathered a difficult couple of years, facing challenges on multiple fronts, including in 2008-09 generic competition for Risperdal and Topamax and the loss of significant DES share...
-
Mylan Launches Generic Version of Famvir® Tablets
Wednesday, April 20, 2011 - 7:32am | 57Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Famciclovir Tablets, 125 mg, 250 mg and 500 mg, the generic version of Novartis' Famvir® Tablets, a treatment for herpes. Famciclovir Tablets had U.S. sales of approximately $196 million for the...
-
Mylan Launches Generic Famvir(R) Tablets (MYL)
Wednesday, April 20, 2011 - 7:31am | 57Mylan (NASDAQ: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Famciclovir Tablets, 125 mg, 250 mg and 500 mg, the generic version of Novartis' Famvir(R) Tablets, a treatment for herpes. Famciclovir Tablets had U.S. sales of approximately $196 million for the 12...
-
CORRECTION: Abbott Lags Guides FY 2011 EPS $4.54-$4.64 (ABT)
Wednesday, April 20, 2011 - 7:29am | 17CORRECTION: Abbott Lags Guides FY 2011 EPS $4.54-$4.64 (NYSE: ABT)
-
Abbott Increases Dividend by 9% to $0.48
Wednesday, April 20, 2011 - 7:27am | 63On Feb. 18, 2011, the board of directors of Abbott (NYSE: ABT) declared the company's quarterly common dividend of 48 cents per share, an increase of 9 percent over the prior year. The cash dividend is payable May 15, 2011, to shareholders of record at the close of business on April 14, 2011....
-
Bank Of America Reports Higher Numbers For Johnson And Johnson
Wednesday, April 20, 2011 - 7:26am | 229According to Bank Of America, Johnson & Johnson (NYSE: JNJ) has under performed the S&P since the beginning of 2010, but yesterday's (19th April) Q1 earnings report suggests a growth inflection point for JNJ (off a low base), which should end JNJ's weak relative stock performance. Bank Of...